Abstracts tagged "Lupus nephritis"

Abstract Number: 684 • 2019 ACR/ARP Annual Meeting
Clinical Biomarkers at Renal Flare Are Associated with Histologic Changes in Repeat Renal Biopsy in Patients with Biopsy-proven Lupus Nephritis
Min Jung Kim¹, Hajeong Lee ¹, Yeong-Wook Song ¹ and Eun Bong Lee ², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul
Background/Purpose: Renal flares are common during treatment of biopsy-proven lupus nephritis (LN). However, it is unknown whether biopsy should be repeated in the event of…
Abstract Number: 1914 • 2019 ACR/ARP Annual Meeting
Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature
Cristina Arriens¹, Quratul Raja ², Syed Ali Husain ², Bessy George ², Majid Abedi ³, Aviva Jacobs ⁴, Timothy Guyon ⁴, Hemani Wijesuriya ³, Teresa Aberle ⁵, Aikaterini Thanou ⁵, Stan Kamp ⁵, Susan R. Macwana ⁵, Eliza F. Chakravarty ¹, Joan T. Merrill ⁶, Judith James ¹, Robert Terbrueggen ⁴ and Joel Guthridge ¹, ¹Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³DxTerity Diagnostics Inc, Anaheim, CA, ⁴DxTerity Diagnostics Inc, Rancho Dominguez, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The interferon (IFN) signature in SLE is well established, distinguishing lupus patients from healthy controls. Additionally, within lupus patients, higher levels of IFN-responsive gene…
Abstract Number: 2741 • 2019 ACR/ARP Annual Meeting
Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States
Fan Zhang¹, Joseph Mears ¹, ilya Korsunsky ¹, Kevin Wei ², Anna Helena Jonsson ², Deepak Rao ¹, Edy Kim ³, Laura Donlin ⁴, Jill Buyon ⁵, Michelle Petri ⁶, Chaim Putterman ⁷, Thomas Tuschl ⁸, Nir Hacohen ⁹, Betty Diamond ¹⁰, Michael Brenner ¹¹ and Soumya Raychaudhuri ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boton, MA, ⁴Hospital For Special Surgery, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Albert Einstein College of Medicine, New York, NY, ⁸Rockefeller Research Laboratories, New York, ⁹Broad Institute, Cambridge, ¹⁰Feinstein Institutes for Medical Research, Manhasset, ¹¹Brigham and Women’s Hospital:, Boston
Background/Purpose: Different autoimmune diseases can co-exist in an individual and share similar genetic associations, autoimmune signaling pathways, and clinical manifestations. However, autoimmune diseases present varied…
Abstract Number: 690 • 2019 ACR/ARP Annual Meeting
Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment
Ranjan Gupta¹, Dipendra Kumar Mitra ¹ and Sonam Rani ¹, ¹All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: Monocytes/macrophages are the most abundant cells infiltrating the glomeruli and in the active urinary sediment of patients with Lupus Nephritis (LN).1 These cells also…
Abstract Number: 1915 • 2019 ACR/ARP Annual Meeting
Validation of a Serologic Antibody Biomarker Against a Candidate Gut Pathobiont for the Diagnosis of Lupus Nephritis
Gregg Silverman¹, Doua Azzouz ¹, Caroline Grönwall ², Iva Gunnarsson ³ and Elisabet Svenungsson ⁴, ¹NYU School of Medicine, New York, NY, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, ³Karolinska Institute, Stockholm, Stockholms Lan, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is the archetypic systemic autoimmune disease, for which there is mounting evidence for roles for intestinal bacteria in the development…
Abstract Number: 2742 • 2019 ACR/ARP Annual Meeting
Toward a Liquid Biopsy for Lupus Nephritis: Urine Proteomic Analysis of SLE Identifies Inflammatory and Macrophage Signatures
Andrea Fava¹, Yuji Zhang ², Jill Buyon ³, H. Michael Belmont ⁴, Peter Izmirly ⁵, Chandra Mohan ⁶, Ting Zhang ⁷, The Accelerating Medicines Partnership ⁸ and Michelle Petri ⁹, ¹Johns Hopkins University, Baltimore, ²University of Maryland, Baltimore, ³NYU School of Medicine, New York, ⁴New York University School of Medicine, Ney York, ⁵New York University School of Medicine, New York, ⁶University of Houston, Houston, ⁷Biomedical Engineering, University of Houston, Houston, TX, ⁸Multiple Organizations, USA, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) complicates up to 60% of patients with systemic lupus erythematosus (SLE) and carries a high morbidity and mortality. The definitive diagnosis…
Abstract Number: 692 • 2019 ACR/ARP Annual Meeting
Correlation of Urinary Soluble CD163 Levels with Clinicopathological Features in Lupus Nephritis: Its Role as a Potential Biomarker
Shilpa Venkataraman¹, Ankita Singh ², Manjula Murari ³, Vinita Agrawal ², Amita Aggarwal ³ and Rakesh Pandey ⁴, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute for Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Lupus nephritis (LN), is seen in 30-50% patients with SLE and 5-10% patients progress to end-stage renal disease. The clinical disease activity indices do…
Abstract Number: 1917 • 2019 ACR/ARP Annual Meeting
Tubulointerstitial Inflammation Predicts Outcomes in Lupus Nephritis
Charles Oshinsky¹, Mariam Siddiqui ², Vladimir Liarski ³, Anthony Chang ³, Marcus Clark ⁴ and Kichul Ko ³, ¹University of Chicago, Department of Internal Medicine, Chicago, ²Northwestern Memorial Hospital, Chicago, ³University of Chicago, Chicago, ⁴University of Chicago, Chicago, IL
Background/Purpose: Lupus nephritis (LuN) causes significant morbidity and mortality, but predicting which patients will progress still remains imprecise. Current classification schema for LuN and its…
Abstract Number: 2894 • 2019 ACR/ARP Annual Meeting
CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity
Evan Der ¹, Ting Zhang ², Chi Chiu Mok ³, Ramesh Saxena ⁴, Krishna R. Polu ⁵, Chandra Mohan ⁶ and Chaim Putterman⁷, ¹Albert Einstein College of Medicine, New York, ²Biomedical Engineering, University of Houston, Houston, TX, ³Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ⁴University of Texas South Western, Dallas, TX, ⁵Equillium, San Diego, CA, ⁶University of Houston, Houston, ⁷Albert Einstein College of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) is a leading cause of morbidity and mortality in Systemic lupus erythematosus (SLE) patients. However, the pathogenesis of renal disease in…
Abstract Number: 859 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of a Randomized Controlled Trial Comparing Tacrolimus with Mycophenolate Mofetil as Induction Therapy of Severe Lupus Nephritis
Chi Chiu Mok¹, Ling Yin Ho ², Shirley Ying ³, Woon Leung Ng ⁴ and Man Chi Leung ⁴, ¹Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Princess Margaret Hospital, Hong Kong, Hong Kong, ⁴United Christian Hospital, Hong Kong, Hong Kong
Background/Purpose: To report the 10-year outcome of patients with lupus nephritis (LN) treated with combined prednisolone with mycophenolate mofetil (MMF) or tacrolimus (TAC) as induction…
Abstract Number: 1918 • 2019 ACR/ARP Annual Meeting
Urine CD163 Significantly Discriminates Active Lupus Nephritis and Strongly Correlates with Proliferative Glomerulonephritis
Ting Zhang¹, Ramesh Saxena ², Chi Chiu Mok ³, Michelle Petri ⁴ and Chandra Mohan ⁵, ¹Biomedical Engineering, University of Houston, Houston, TX, ²UTSW, Dallas, ³Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Houston, Houston
Background/Purpose: CD163 is a marker for alternatively activated M2 macrophages, which have been implicated in the pathogenesis of lupus nephritis (LN). The potential of urine…
Abstract Number: 2895 • 2019 ACR/ARP Annual Meeting
Complement Protein CL-K1 at High Concentrations Protects Against the Development of Lupus Nephritis
Anne Troldborg¹, Anne Voss ², Søren Werner Karlsjov Hansen ³, Jens Christian Jensenius ⁴, Kristian Stengaard-Pedersen ⁵ and Steffen Thiel ⁶, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Odense University Hospital, Department of Rheumatology, Odense, Denmark, ³University of Southern Denmark, Odense, Denmark, ⁴Aarhus University, department of biomedicine, Aarhus, Denmark, ⁵Department of Rheumatology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus University, Aarhus, Denmark, Aarhus, Denmark, ⁶Department of Biomedicine, Aarhus University, Aarhus, Denmark, Aarhus, Denmark
Background/Purpose: Nephritis is a severe manifestation of systemic lupus erythematosus (SLE) that develops in 30 to 50 percent of the patients. At the time of…
Abstract Number: 880 • 2019 ACR/ARP Annual Meeting
Diseased Lupus Nephritis Kidneys Serve as a Primary Site of Systemic Autoimmune Development
Matthew Woodruff¹, Christopher Tipton ¹, Jennifer Hom ¹ and Iñaki Sanz ¹, ¹Emory University, Atlanta, GA
Background/Purpose: Lupus nephritis (LN) is an autoimmune destruction of the kidney glomeruli and loss of kidney function affecting almost half of lupus patients. Although the…
Abstract Number: 1930 • 2019 ACR/ARP Annual Meeting
Analysis of Lupus Nephritis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated Within Infiltrating Cells
Adam Labonte¹, Jackson Xu ², Sarah Heuer ², Robert Robl ², Prathyusha Bachali ¹, Michelle Catalina ¹, Peter Lipsky ³ and Amrie Grammer ⁴, ¹AMPEL Biosolutions and the RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions, Charlottesville, VA, ³AMPEL BioSolutions, LLC, Charlottesville, VA, ⁴AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA
Background/Purpose: LN is a serious complication of SLE that affects about 20-40% of all lupus patients and leads to kidney damage, end-stage renal disease, and…
Abstract Number: 2896 • 2019 ACR/ARP Annual Meeting
The Role of Alterations in the Splicing Machinery in the Pathogenesis of Lupus: Does It Impact Lupus Nephritis?
Chary Lopez-Pedrera¹, Alejandro Ibañez-Costa ¹, Mª Ángeles Aguirre-Zamorano ², Laura Pérez-Sanchez ³, Alejandra Patiño-Trives ¹, Maria Luque-Tevar ¹, Maria del Carmen Abalos-Aguilera ¹, Ivan Arias de la Rosa ⁴, Nuria Barbarroja ⁵, Mario Espinosa ⁶, Eduardo Collantes-Estevez ⁴, Justo Castaño ⁷, Raúl Luque ⁷ and Carlos Perez-Sanchez ⁸, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁶UGC de Nefrología. Hospital Universitario Reina Sofía, Cordoba, Spain, ⁷Maimónides Institute for Biomedical Research at Córdoba, Cordoba, Spain, ⁸Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain
Background/Purpose: The aim of this study was to evaluate whether alterations in the splicing machinery of immune cells could influence the development and activity of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.